Webcasts for Major Research at IAS 2011July/August 2011 This year's meeting had three main areas of interest. Firstly, treatment as prevention -- most notably in a study called HPTN-052 and PrEP studies. The Treatment Is Prevention session include links to abstracts, slides and webcasts from the HPTN-052 study. http://pag.ias2011.org/session.aspx?s=98 Tony Fauci: 30 years of HIV/AIDS: a scientific journey and a look to the future http://pag.ias2011.org/flash.aspx?pid=409 Towards an HIV cure: insight into residual viral replication, establishment of reservoirs and understanding mechanisms of persistence http://pag.ias2011.org/session.aspx?s=70 Towards an HIV cure: new strategies for an old challenge http://pag.ias2011.org/session.aspx?s=15 Controversies in HIV cure research satellite meeting http://pag.ias2011.org/session.aspx?s=39 Thirdly, there were important studies about New drugs and diagnostics and new strategies with oral presentations on new integrase inhibitors (elvitegravir and dolutegravir) and NNRTIs (lersivirine), using of HSV drugs (acyclovir/valacyclovir) and currently approved meds (maraviroc/atazanavir). Plus, also in the late breaker session, an exciting new rapid antibody test for cryptococcal meningitis developed in the UK that can be used at the point of care. These were presented mainly in the following two sessions. New drugs and strategies http://pag.ias2011.org/session.aspx?s=55 Late breaker Track B http://pag.ias2011.org/session.aspx?s=44 Links to external websites are current at time of posting but not maintained. ![]() Treatment Is Prevention: ARV Treatment in HPTN-052 Reduces Transmission by at Least 96%: Single Transmission in Treatment Arm Occurred Prior to Viral Suppression This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|